Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients

Haematologica. 2016 Mar;101(3):e86-90. doi: 10.3324/haematol.2015.135103. Epub 2015 Dec 3.
No abstract available

Keywords: BCR-ABL; cardiovascular events; chronic phase CML; homocysteine; nilotinib.

Publication types

  • Letter
  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Cholesterol, HDL / blood
  • Coronary Artery Disease / blood
  • Coronary Artery Disease / etiology*
  • Coronary Artery Disease / pathology
  • Coronary Artery Disease / prevention & control
  • Drug Administration Schedule
  • Female
  • Homocysteine / blood
  • Humans
  • Hyperhomocysteinemia / blood
  • Hyperhomocysteinemia / complications
  • Hyperhomocysteinemia / drug therapy*
  • Hyperhomocysteinemia / pathology
  • Imatinib Mesylate / therapeutic use*
  • Leukemia, Myeloid, Chronic-Phase / blood
  • Leukemia, Myeloid, Chronic-Phase / complications
  • Leukemia, Myeloid, Chronic-Phase / drug therapy*
  • Leukemia, Myeloid, Chronic-Phase / pathology
  • Male
  • Middle Aged
  • Prospective Studies
  • Pyrimidines / administration & dosage
  • Pyrimidines / adverse effects*
  • Retrospective Studies
  • Triglycerides / blood

Substances

  • Antineoplastic Agents
  • Cholesterol, HDL
  • Pyrimidines
  • Triglycerides
  • Homocysteine
  • Imatinib Mesylate
  • nilotinib